FDA Rejects ITM-11 Radiopharmaceutical Therapy Over Manufacturing Issues
The Food and Drug Administration has rejected ITM Isotope Technologies Munich SE’s radiopharmaceutical therapy, ITM-11, citing manufacturing issues in a decision that halts a competitor to Novartis’s existing market treatments. The setback stalls the clinical advancement of a radiopharmaceutical therapy designed to deliver radioactive isotopes directly to cancer cells.
- Clinical trial data released in March 2025 showed patients receiving ITM-11 achieved a progression-free survival rate of 23.9 months.
- Existing market alternatives, such as everolimus, yield a median progression-free survival rate of 14.1 months for the same patient demographic.
Regulatory Rejection Halts Competition in Neuroendocrine Tumors
The decision by federal regulators impacts the development timeline for ITM-11, which was engineered to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These rare malignancies develop within the pancreas, stomach, small intestine, and other sections of the gastrointestinal tract.
Before this regulatory hurdle, clinical data pointed toward significant efficacy gains over current standard-of-care options. ITM reported in March 2025 that patients with early-stage GEP-NETs who received ITM-11 infusions experienced 23.9 months without tumor progression. In comparison, clinical data for patients taking everolimus, an established alternative on the market, demonstrated a median progression-free survival of 14.1 months.
Manufacturing Compliance and Supply Chain Standards in Radiopharmaceuticals
The rejection forces ITM Isotope Technologies Munich SE to address the specific manufacturing deficiencies cited by the agency before resubmitting the application.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*